

Application Serial No. 10/027,603
Amendment dated February 17, 2006
Reply to Office Action of November 18, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1-79. (cancelled)
80. (currently amended) An antibody or antibody fragment thereof that specifically binds residues 20-105 of SEQ ID NO:2 and inhibits EG-VEGF induced proliferation of endothelial cells.
81. (currently amended) The antibody or antibody fragment thereof of claim 80, wherein the antibody ~~or antibody fragment~~ is a monoclonal antibody ~~or monoclonal antibody fragment~~.
82. (currently amended) The antibody or antibody fragment thereof of claim 80, wherein the antibody ~~or antibody fragment~~ is a chimeric antibody ~~or chimeric antibody fragment~~.
83. (currently amended) The antibody or antibody fragment thereof of claim 80, wherein the antibody is a humanized antibody ~~or humanized antibody fragment~~.
84. (currently amended) The ~~antibody or~~ antibody fragment of claim 80, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
85. (currently amended) The antibody or antibody fragment thereof of claim 81, wherein the monoclonal antibody is produced by a hybridoma having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.
- 86-93. (cancelled)
94. (currently amended) A composition comprising the antibody or antibody fragment thereof of claim 80 in admixture with a carrier.

Application Serial No. 10/027,603
Amendment dated February 17, 2006
Reply to Office Action of November 18, 2005

95. (previously presented) The composition of claim 94, wherein the carrier is a pharmaceutically acceptable carrier.
96. (currently amended) The composition of claim 94, wherein the antibody ~~or antibody fragment~~ is a monoclonal antibody ~~or monoclonal antibody fragment~~.
97. (currently amended) The composition of claim 94, wherein the antibody ~~or antibody fragment~~ is a chimeric antibody ~~or chimeric antibody fragment~~.
98. (currently amended) The composition of claim 94, wherein the antibody ~~or antibody fragment~~ is a humanized antibody ~~or humanized antibody fragment~~.
99. (currently amended) The composition of claim 94, wherein the ~~antibody or~~ antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
100. (currently amended) The composition of claim 96, wherein the monoclonal antibody is produced by a hybridoma having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.
- 101-103. (cancelled)
104. (previously presented) An article of manufacture, comprising:
- (a) a container;
 - (b) a label on the container; and
 - (c) the composition of claim 95.
105. (canceled)
106. (currently amended) The ~~antibody or~~ antibody fragment of claim 81, wherein the ~~monoclonal antibody fragment~~ is a fragment of a monoclonal antibody produced by a hybridoma having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

Application Serial No. 10/027,603
Amendment dated February 17, 2006
Reply to Office Action of November 18, 2005

107. (currently amended) The composition of claim 96, wherein the ~~monoclonal~~-antibody fragment is a fragment of a monoclonal antibody produced by a hybridoma having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

108. (currently amended) An antagonist of EG-VEGF, wherein the antagonist comprises an antibody or antibody fragment that specifically binds a polypeptide comprising SEQ ID NO:2 and inhibits EG-VEGF induced endothelial cell proliferation.